Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques

Vaccine

Volumn 28, Issue 3, 2010, Pages 780-789

  Itoh, Yasushi ^a   Ozaki, Hiroichi ^b   Ishigaki, Hirohito ^a   Sakoda, Yoshihiro ^c   Nagata, Tomoya ^a   Soda, Kosuke ^c   Isoda, Norikazu ^c   Miyake, Taichiro ^a   Ishida, Hideaki ^a   Okamoto, Kiyoko ^a   Nakayama, Misako ^a   Tsuchiya, Hideaki ^a   Torii, Ryuzo ^a   Kida, Hiroshi ^c,d   Ogasawara, Kazumasa ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

H7N7; Highly pathogenic avian influenza virus; Non human primate

Indexed keywords

ALUMINUM POTASSIUM SULFATE; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; BODY TEMPERATURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; INFLUENZA VIRUS A H7N7; LYMPHOCYTE PROLIFERATION; MACACA; NONHUMAN; NOSE SMEAR; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEVER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, SUBCUTANEOUS; MACACA FASCICULARIS; NASAL CAVITY; ORTHOMYXOVIRIDAE INFECTIONS; TIME FACTORS; TRACHEA;

EID: 71149112570     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.067     Document Type: Article

References (40)

1. Belser J.A., Lu X., Maines T.R., Smith C., Li Y., Donis R.O., et al. Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol 81 20 (2007) 11139-11147
2. Joseph T., McAuliffe J., Lu B., Jin H., Kemble G., and Subbarao K. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol 81 19 (2007) 10558-10566
3. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 101 5 (2004) 1356-1361
4. van Beest Holle M.D.R., Meijer A., Koopmans M., de Jager C.M., van de Kamp E.E.H.M., Wilbrink B., et al. Human-to-human transmission of avian influenza A/H7N7, the Netherlands, 2003. Eurosurveiillance 10 10-12 (2005) 264-268
5. Hirst M., Astell C.R., Griffith M., Coughlin S.M., Moksa M., Zeng T., et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 10 12 (2004) 2192-2195
6. Puzelli S., Di Trani L., Fabiani C., Campitelli L., De Marco M.A., Capua I., et al. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis 192 8 (2005) 1318-1322
7. Belser J.A., Blixt O., Chen L.M., Pappas C., Maines T.R., Van Hoeven N., et al. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad Sci USA 105 21 (2008) 7558-7563
8. de Wit E., Munster V.J., Spronken M.I., Bestebroer T.M., Baas C., Beyer W.E., et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 79 19 (2005) 12401-12407
9. Jadhao S.J., Achenbach J., Swayne D.E., Donis R., Cox N., and Matsuoka Y. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 26 14 (2008) 1742-1750
10. Sakabe S., Sakoda Y., Haraguchi Y., Isoda N., Soda K., Takakuwa H., et al. A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens. Vaccine 26 17 (2008) 2127-2134
11. Itoh Y., Ozaki H., Tsuchiya H., Okamoto K., Torii R., Sakoda Y., et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26 4 (2008) 562-572
12. Sawai T., Itoh Y., Ozaki H., Isoda N., Okamoto K., Kashima Y., et al. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124 2 (2008) 155-165
13. Gao P., Watanabe S., Ito T., Goto H., Wells K., McGregor M., et al. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 73 4 (1999) 3184-3189
14. Lu X., Tumpey T.M., Morken T., Zaki S.R., Cox N.J., and Katz J.M. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73 7 (1999) 5903-5911
15. Zitzow L.A., Rowe T., Morken T., Shieh W.J., Zaki S., and Katz J.M. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76 9 (2002) 4420-4429
16. Govorkova E.A., Rehg J.E., Krauss S., Yen H.L., Guan Y., Peiris M., et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79 4 (2005) 2191-2198
17. Staeheli P., Grob R., Meier E., Sutcliffe J.G., and Haller O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol Cell Biol 8 10 (1988) 4518-4523
18. Kida H., and Sakoda Y. Library of influenza virus strains for vaccine and diagnostic use against highly pathogenic avian influenza and human pandemics. Dev Biol (Basel) 124 (2006) 69-72
19. Soda K., Sakoda Y., Isoda N., Kajihara M., Haraguchi Y., Shibuya H., et al. Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res 55 2-3 (2008) 93-98
20. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., and Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 61 1 (1985) 143-151
21. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11 3 (1993) 293-306
22. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 5 (2004) 497-505
23. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 4 (2008) 869-882
24. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 7198 (2008) 1122-1126
25. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 8 (2008) 847-856
26. Li H., Willingham S.B., Ting J.P., and Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181 1 (2008) 17-21
27. Manzoor R., Sakoda Y., Sakabe S., Mochizuki T., Namba Y., Tsuda Y., et al. Development of a pen-site test kit for the rapid diagnosis of H7 highly pathogenic avian influenza. J Vet Med Sci 70 6 (2008) 557-562
28. Thomas M.J., Flanary L.R., Brown B.A., Katze M.G., and Baskin C.R. Use of human nasal cannulas during bronchoscopy procedures as a simple method for maintaining adequate oxygen saturation in pigtailed macaques (Macaca nemestrina). J Am Assoc Lab Anim Sci 45 4 (2006) 44-48
29. Kida H., Brown L.E., and Webster R.G. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122 1 (1982) 38-47
30. Yoden S., Kida H., and Yanagawa R. An avian influenza virus of which infectivity is neutralized by antisera lacking hemagglutination-inhibition activity. Arch Virol 74 2-3 (1982) 205-210
31. Kida H., Yoden S., Kuwabara M., and Yanagawa R. Interference with a conformational change in the haemagglutinin molecule of influenza virus by antibodies as a possible neutralization mechanism. Vaccine 3 (1985) 219-222
32. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 102 36 (2005) 12915-12920
33. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24 1 (1986) 157-160
34. Notka F., Stahl-Hennig C., Dittmer U., Wolf H., and Wagner R. Construction and characterization of recombinant VLPs and Semliki-forest virus live vectors for comparative evaluation in the SHIV monkey model. Biol Chem 380 3 (1999) 341-352
35. Palker T.J., Monteiro J.M., Martin M.M., Kakareka C., Smith J.F., Cook J.C., et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19 27 (2001) 3733-3743
36. Speidel K., Osen W., Faath S., Hilgert I., Obst R., Braspenning J., et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 27 9 (1997) 2391-2399
37. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., and Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26 19 (2008) 2350-2359
38. Perales M.A., Schwartz D.H., Fabry J.A., and Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 10 1 (1995) 27-35
39. Benson E.M., Clarkson J., Law M., Marshall P., Kelleher A.D., Smith D.E., et al. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res Hum Retroviruses 15 2 (1999) 105-113
40. Martinon F., Petrilli V., Mayor A., Tardivel A., and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 7081 (2006) 237-241